Viewing Study NCT06518408



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06518408
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: None
First Post: 2024-07-09

Brief Title: A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
Sponsor: None
Organization: None

Study Overview

Official Title: A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CABO-CHANCE
Brief Summary: The CABOTEGRAVIR Long Acting RILPIVIRENE Long Acting regimen was currently endorsed by guidelines worldwide as an option for the Treatment of HIV-1 Infection however collecting real-world data closer to clinical practice use is still necessary This study also registers some immunological metabolicanti-inflammatory parameters and fat distribution analysis to observe a hypothetical improvement on these parameters

Psychosocial aspects are also very important in these patients as these patients may suffer social stigma and therefore suffer certain psychological disorders Patient experience data will be assessed through PROs and bespoke single-item questions to collect patient perception of treatment and register psychosocial aspects related to their health status
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None